FDA Panel Weighs Guidelines For Human Clinical Trials Involving Treatments From Embryonic Stem Cells
Apr 17th 2008Drug InformationStem Cell Research
Because of the potential risks involved in human embryonic stem cells, data on the effectiveness of treatments using them “may need to be particularly strong,” Steven Bauer, chief of FDA’s cell and tissue therapy branch, said in a presentation to the FDA advisory
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
